Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Nisha Pippal, Sumita Halder, Shruti Srivastava, Rajarshi Kar, Rachna Gupta & Almeida Edelbert Anthonio. (2022) Correlation between telomere length and efficacy of oral and long-acting injectable antipsychotics on severity and cognitive impairment of schizophrenia. International Journal of Psychiatry in Clinical Practice 26:2, pages 157-164.
Read now
Read now
Wenjie Zhang, Tony B Amos, Stephen W Gutkin, Nicole Lodowski, Emma Giegerich & Kruti Joshi. (2018) A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. ClinicoEconomics and Outcomes Research 10, pages 309-320.
Read now
Read now
Jacqueline A. Pesa, Dilesh Doshi, Li Wang, Huseyin Yuce & Onur Baser. (2017) Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Current Medical Research and Opinion 33:4, pages 723-731.
Read now
Read now
Jörg Mahlich, Masamichi Nishi & Yoshimichi Saito. (2015) Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. ClinicoEconomics and Outcomes Research 7, pages 267-272.
Read now
Read now
Nesrin Dilbaz. (2015) New Targets for the Management of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25:4, pages 407-428.
Read now
Read now
John M. Kane, Cathy Zhao, Brian R. Johnson, Ross A. Baker, Anna Eramo, Robert D. McQuade, Anna R. Duca, Raymond Sanchez & Timothy Peters-Strickland. (2015) Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics 18:2, pages 145-154.
Read now
Read now
Kimberly M Shuler. (2014) Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Preference and Adherence 8, pages 701-714.
Read now
Read now
Leslie Citrome, Siddhesh A. Kamat, Christophe Sapin, Ross A. Baker, Anna Eramo, Jesse Ortendahl, Benjamin Gutierrez, Karina Hansen & Tanya G. K. Bentley. (2014) Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics 17:8, pages 567-576.
Read now
Read now
Gabriel Kaplan, Julio Casoy & Jacqueline Zummo. (2013) Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Preference and Adherence 7, pages 1171-1180.
Read now
Read now
Tatiana Dilla, Antonio Ciudad & María Álvarez. (2013) Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Preference and Adherence 7, pages 275-284.
Read now
Read now
Thomas R. Einarson & Michiel E. H. Hemels. (2013) Validation of an economic model of paliperidone palmitate for chronic schizophrenia. Journal of Medical Economics 16:11, pages 1267-1274.
Read now
Read now
John M. Kane, Raymond Sanchez, Joan Zhao, Anna R. Duca, Brian R. Johnson, Robert D. McQuade, Anna Eramo, Ross A. Baker & Timothy Peters-Strickland. (2013) Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics 16:7, pages 917-925.
Read now
Read now
Leslie Citrome. (2013) New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Review of Neurotherapeutics 13:7, pages 767-783.
Read now
Read now
Rimal Bera, Steve Offord, Donna Zubek, Gina Lau, Jay Lin, Ross A. Baker & Craig Karson. (2013) Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. Journal of Medical Economics 16:4, pages 522-528.
Read now
Read now
Articles from other publishers (7)
Claus Wolff-Menzler, Jörg Mahlich, Kerstin Olbrich, Adrian Wilk & Antonie Wimmer. (2021) Hospitalisierungen und Behandlungskosten von Schizophreniepatienten nach Umstellung auf Depot-Antipsychotika. Gesundheitsökonomie & Qualitätsmanagement 26:06, pages 302-309.
Crossref
Crossref
Nora Palomar-Ciria, Marta Migoya-Borja, Fanny Cegla-Schvartzman, Santiago Ovejero, Raquel Alvarez-Garcia, Hugo J. Bello & Enrique Baca-García. (2021) Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International Clinical Psychopharmacology 36:2, pages 97-100.
Crossref
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study. Clinical Drug Investigation 40:4, pages 355-375.
Crossref
Crossref
Aurélie Schoubben, Maurizio Ricci & Stefano Giovagnoli. (2019) Meeting the unmet: from traditional to cutting-edge techniques for poly lactide and poly lactide-co-glycolide microparticle manufacturing. Journal of Pharmaceutical Investigation 49:4, pages 381-404.
Crossref
Crossref
Seon-Cheol Park, Mi Young Choi, Jina Choi, Eunjung Park, Ha Jin Tchoe, Jae Kyung Suh, Young Hoon Kim, Seung Hee Won, Young-Chul Chung, Kyung-Yeol Bae, Sang-Kyu Lee, Chan Mi Park & Seung-Hwan Lee. (2018) Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis. Clinical Psychopharmacology and Neuroscience 16:4, pages 361-375.
Crossref
Crossref
Aleksandra Dutina & Ivana Stašević-Karličić. (2018) Pharmacoeconomic aspects of schizophrenia. Racionalna terapija 10:1, pages 37-41.
Crossref
Crossref
N. Kirk Morton & Donna Zubek. (2013) Adherence Challenges and Long-Acting Injectable Antipsychotic Treatment in Patients with Schizophrenia. Journal of Psychosocial Nursing and Mental Health Services 51:3, pages 13-18.
Crossref
Crossref